Mineralys Therapeutics (MLYS) Aktievy
Mineralys Therapeutics, Inc. är ett biofarmaceutiskt företag som utvecklar läkemedel mot sjukdomar som drivs av dysreglerat aldosteron i USA. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 3/6 |
| Framtida tillväxt | 2/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 5/6 |
| Utdelningar | 0/6 |
MLYS Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Mineralys Therapeutics, Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$24.18 |
| 52 veckors högsta | US$47.65 |
| 52 veckors lägsta | US$12.59 |
| Beta | 0.56 |
| 1 månads förändring | -18.14% |
| 3 månaders förändring | -13.55% |
| 1 års förändring | 50.84% |
| 3 års förändring | 52.84% |
| 5 års förändring | n/a |
| Förändring sedan börsintroduktionen | 31.13% |
Senaste nyheter och uppdateringar
Recent updates
Mineralys: 'Hold' As Hypertension OSA Data Barely Delivers And AstraZeneca On The Move
Summary Mineralys is downgraded from 'Strong Buy' to 'Hold' due to competitive and clinical setbacks. MLYS's lorundrostat NDA was accepted by the FDA with a PDUFA date of December 22, 2026, targeting uncontrolled/resistant hypertension. Failure to meet the primary endpoint in the OSA hypertension subpopulation and AstraZeneca's earlier PDUFA for baxdrostat create significant headwinds. MLYS remains well-capitalized, with cash runway into 2028 and further ATM capacity, but faces execution and competitive risks. Read the full article on Seeking Alpha
Regulatory And Competitive Pressures Will Challenge Hypertension Launch Yet Longer Term Potential Remains
Catalysts About Mineralys Therapeutics Mineralys Therapeutics is a biopharmaceutical company focused on developing lorundrostat, an aldosterone synthase inhibitor for adults with uncontrolled or resistant hypertension and related comorbidities. What are the underlying business or industry changes driving this perspective?
Hypertension PDUFA Decision And Large Target Population Will Support Strong Long Term Opportunity
Catalysts About Mineralys Therapeutics Mineralys Therapeutics is a biopharmaceutical company focused on developing lorundrostat, an aldosterone synthase inhibitor for patients with uncontrolled and resistant hypertension. What are the underlying business or industry changes driving this perspective?
Hypertension And Cardiorenal Catalysts Will Reshape Long Term Prospects For This Biotech
Catalysts About Mineralys Therapeutics Mineralys Therapeutics is a biopharmaceutical company focused on developing lorundrostat, an aldosterone synthase inhibitor, for patients with uncontrolled and resistant hypertension and related cardiorenal conditions. What are the underlying business or industry changes driving this perspective?Will Mineralys Therapeutics (NASDAQ:MLYS) Spend Its Cash Wisely?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Mineralys: Prospects Just Got Better With Successful Pivotal Data Readouts
Summary Primary endpoints of both Advance-HTN and Launch-HTN studies, using lorundrostat to treat patients with hypertension were met with statistical significance. Upcoming catalysts include the full data release from Advance-HTN in March 2025 and phase 2 Explore-CKD trial results in Q2 2025. Financially, company has $198.2 million in cash but may need to raise funds soon, potentially diluting shareholders. The Anti-Hypertensive drugs market worldwide is expected to reach $22.41 billion by 2025. Read the full article on Seeking AlphaIs Mineralys Therapeutics (NASDAQ:MLYS) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Mineralys Therapeutics: Lorundrostat Is Worth A Shot In 2025 For Hypertension
Summary I believe Mineralys Therapeutics has a promising candidate with Lorundrostat for hypertension, CKD, and OSA. It should report more key pivotal clinical data this year. MLYS has several Phase 2 and 3 trials on Lorundrostat that could position it favorably for a potential FDA submission by late 2026 or sometime in 2027. According to the company’s slides, Lorundrostat seems to have superior selectivity in some patients that reduces cortisol suppression and other side effects. My main concern with MLYS is its relatively short cash runway. But still, I think it has enough runway to fund its key trials through 2025. Overall, I feel MLYS is a good speculative “Buy” at these levels, especially after a substantial pullback in the shares with promising catalysts lined up in 2025. Read the full article on Seeking AlphaHere's Why We're Not Too Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Mineralys In Hypertension: Upcoming Catalysts And Strong Positioning
Summary Mineralys' lorundrostat, a selective aldosterone synthase inhibitor, shows promise in treating resistant hypertension with fewer side effects compared to current MRAs. Upcoming catalysts include pivotal phase 2 and 3 trial results in 2025, with significant potential market impact if successful. Despite a solid cash position, further funding may be needed for regulatory stages, making acquisition by a major player a strategic move. Given its potential and current valuation, I recommend a cautious buy for Mineralys at these prices. Read the full article on Seeking AlphaWe're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Mineralys Therapeutics: A Story To Keep An Eye On
Summary Today, we look at Mineralys Therapeutics, a clinical-stage biotechnology company focused on developing treatments for diseases driven by elevated aldosterone levels. The company's sole asset, lorundrostat, is an aldosterone synthase inhibitor that has shown promising results in Phase 2 trials for the treatment of uncontrolled hypertension. Mineralys is conducting two additional trials for lorundrostat and is also evaluating its potential for the treatment of hypertension in patients with chronic kidney disease. A full investment analysis follows in the paragraphs below. Read the full article on Seeking AlphaMineralys: 2nd Half 2024 Hypertension Data Readout
Summary Mineralys Therapeutics, Inc. has two ongoing studies evaluating use of lorundrostat for the treatment of patients with uncontrolled or resistant hypertension; these are ADVANCE-HTN and LAUNCH-HTN. Results from the phase 3 ADVANCE-HTN study using lorundrostat for the treatment of patients with uncontrolled or resistant hypertension, expected in the 2nd half of 2024. Mineralys is also conducting a phase 2 study for the use of lorundrostat in treating hypertension in Chronic Kidney Disease patients, with results expected in the first half of 2024 or Q1 2025. The global hypertension market is expected to reach $43.18 billion by 2030. Read the full article on Seeking AlphaWe're Hopeful That Mineralys Therapeutics (NASDAQ:MLYS) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Aktieägarnas avkastning
| MLYS | US Biotechs | US Marknad | |
|---|---|---|---|
| 7D | -16.2% | 2.1% | -3.3% |
| 1Y | 50.8% | 25.0% | 22.3% |
Avkastning vs industri: MLYS översteg US Biotechs branschen som gav 25 % under det senaste året.
Avkastning vs Marknaden: MLYS översteg US marknaden som gav 22.3 % under det senaste året.
Prisvolatilitet
| MLYS volatility | |
|---|---|
| MLYS Average Weekly Movement | 10.4% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stabil aktiekurs: MLYS har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: MLYS s veckovolatilitet ( 10% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2019 | 76 | Jon Congleton | mineralystx.com |
Mineralys Therapeutics, Inc. är ett biofarmaceutiskt företag som utvecklar läkemedel mot sjukdomar som drivs av dysreglerat aldosteron i USA. Företaget utvecklar lorundrostat, en patentskyddad, oralt administrerad, mycket selektiv aldosteronsyntashämmare för behandling av kardiorenala tillstånd som påverkas av dysreglerat aldosteron, såsom högt blodtryck, kronisk njursjukdom och obstruktiv sömnapné. Bolaget var tidigare känt som Catalys SC1, Inc. och bytte namn till Mineralys Therapeutics, Inc. i maj 2020.
Mineralys Therapeutics, Inc. Sammanfattning av grunderna
| MLYS grundläggande statistik | |
|---|---|
| Börsvärde | US$1.86b |
| Vinst(TTM) | -US$151.78m |
| Intäkter(TTM) | n/a |
Är MLYS övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| MLYS resultaträkning (TTM) | |
|---|---|
| Intäkter | US$0 |
| Kostnad för intäkter | US$0 |
| Bruttovinst | US$0 |
| Övriga kostnader | US$151.78m |
| Intäkter | -US$151.78m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | -1.84 |
| Bruttomarginal | 0.00% |
| Nettovinstmarginal | 0.00% |
| Skuld/egenkapitalförhållande | 0% |
Hur har MLYS utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/06/09 17:25 |
| Aktiekurs vid dagens slut | 2026/06/09 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Mineralys Therapeutics, Inc. bevakas av 9 analytiker. 8 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Umer Raffat | Evercore ISI |
| Richard J. Law | Goldman Sachs |